Nutra Pharma Corp.

NPHC

US67060U2087

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:50:57 2024-05-01 am EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

Mar. 22	Nutra Pharma Corporation Appoints Michael Flax as CFO	CI
Mar. 22	Nutra Pharma Corporation Announces Management Changes	CI

Nutra Pharma Corp. Announces Resignation of Dan Oran, Director

March 07, 2018 at 04:11 pm EST

Nutra Pharma Corp. announced that on February 23, 2018, Dan Oran, Director since July 21, 2016, resigned as a Director of Board of Directors.

Latest news about Nutra Pharma Corp.

Nutra Pharma Corporation Appoints Michael Flax as CFO	Mar. 22	CI
Nutra Pharma Corporation Announces Management Changes	Mar. 22	CI
Nutra Pharma Corporation Announces CEO Changes	Mar. 22	CI
Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Nutra Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-20	CI
Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Nutra Pharma Announces First Manufacturing Agreement	22-03-23	CI
Nutra Pharma Expands Manufacturing Capabilities	22-03-17	CI
Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	21-07-01	CI
Nutra Pharma Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	21-05-07	CI
Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	21-02-05	CI
Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	21-02-04	CI
Nutra Pharma Announces Availability of Nyloxin on the iRemedy Marketplace	19-05-30	CI
Nutra Pharma and JAH Neal Holdings LLC Sign Definitive Letter of Intent for $4 Million Joint Venture Financing	18-06-28	CI
Nutra Pharma Corporation Partners with NxGen Brands, LLC for Nyloxin Distribution	18-04-19	CI
Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	18-04-16	CI
Nutra Pharma Corporation Files Provisional Patent for the Treatment of Amyotrophic Lateral Sclerosis	18-04-10	CI
Nutra Pharma Corp. Announces Resignation of Dan Oran, Director	18-03-07	CI
Nutra Pharma Corporation Signs Definitive Distribution Agreement with Pharmachal PTY LTD	18-02-01	CI
Nutra Pharma Corporation Partners with EuroAmerican IP, LLC to Distribute Nyloxin for Sale to Government Agencies	18-01-18	CI
Nutra Pharma Corp. Launches Luxury Feet	17-06-21	CI
Nutra Pharma Corporation Announces Collaboration with International Security Group to Develop Nerve Agent Counter Measures	17-05-23	CI

Nutra Pharma Corp. is a holding company, which owns intellectual property and operates in the biotechnology industry. The Company conducts drug discovery research and development activities on its own and through its subsidiary, ReceptoPharm, Inc. Its first consumer product, Cobroxin, is an over-the-counter pain reliever designed to treat moderate to severe chronic pain. Its second consumer product, Nyloxin, is an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain. Pet Pain-Away is an over-the-counter pain reliever designed to treat pain in cats and dogs. Equine Pain-Away is an over-the-counter topical pain reliever designed to treat pain and inflammation in horses. Its Luxury Feet is an over-the-counter pain reliever designed specifically to treat foot pain and inflammation, especially for women who wear high heels and stilettos. The Company also manufactures Cell Defender, ZMUNITY, and Avini Plus Energy, among others.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUTRA PHARMA CORP.	+9,900.00%	706K
MODERNA, INC.	+26.28%	42.68B
IQVIA HOLDINGS INC.	-3.99%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B
BIO-TECHNE CORPORATION	-2.02%	11.55B

Other Biotechnology & Medical Research